all report title image
  • Published On : Jan 2022
  • Code : CMI4888
  • Industry : Medical Devices
  • Pages : 222
  • Formats :

Injectable drug delivery systems are used for aesthetic treatments such as body shaping, skin tightening, and wrinkle treatment. As new treatment options there are various route of administration to enter the patient’s body such as intramuscular, intravenous, and subcutaneous as advanced in medical technology. For research and development of several antibiotics, liquid drugs, and vaccination to cure aesthetic problems, companies are investing huge amount in advanced medical technology.

According to the U.S. Food and Drug Administration, 97% of medications & vaccines are administered through injections. Major injectable drugs includes remicade, avastin, neulasta, rituxan, etc. in Brazil. 

The Brazil injectable drugs market for hospitals & ambulatory settings is estimated to be valued at US$ 7,960.0 million in 2021 and is expected to exhibit a CAGR of 8.4% over the forecast period (2021-2028).

Figure 1. Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings Value (US$ Mn), By Product Type, 2021

Brazil Injectable Drugs  | Coherent Market Insights

Market players are focusing on expanding production capacity in different regions globally to strengthen its position in the potential market, which is expected to boost the market growth over the forecast period.

For instance, in March 2020, Brazil initiated its National Flu Vaccination Campaign in three phases against influenza. The vaccine is indicated for anyone over 6 months of age, except those who have had allergic reactions to previous doses.

CMI table icon

Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 7,960.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 8.4% 2028 Value Projection: US$ 17,858.5 Mn
Geographies covered:
  • Region: Brazil
Segments covered:
  • By Product Type: Pre-filled syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, Others
  • By Drug Class: Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-Thrombolytic, Muscle Relaxant, Non Opioids, Opioids, Sedatives, Others
  • By Mode of Delivery: Intramuscular (IM), Intravenous (IV), Subcutaneous (SC), Others (Epidural and Intrathecal)
Companies covered:

Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, B. Braun Medical Inc., Grifols S.A, Baxter International, Inc., Fresenius Kabi AG, Mylan N.V., Bayer AG, F. Hoffmann-La Roche AG, Farmoquimica S.A., Novartis International AG, Eli Lily and Company, União Química Farmacêutica, Nacional S.A., Cristália, Aspen Pharmacare Holdings Limited, Blau Farmaceutica S.A., Halex Istar Indústria, Farmacêutica SA, Eurofarma, Ache Laboratorios Farmaceuticos SA, Laboratorio Teuto Brasileiro S/A, EMS Pharma, and Hipolabor Farmaceutica Ltda.

Growth Drivers:
  • Increasing government initiatives in the healthcare sector of Brazil
  • Increasing drug launches and approvals
  • Increasing prevalence of chronic diseases
Restraints & Challenges:
  • Various drawbacks in the healthcare system of Brazil
Opportunities:
  • Increasing medical tourism and expansion of pharmaceutical companies in Brazil

Figure 1.1 Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings Value (US$ Mn), By Product Type, 2028

Brazil Injectable Drugs  | Coherent Market Insights

The increasing product launches and approvals are expected to drive the market growth over the forecast period.

For instance, in August 2020, Becton Dickinson Company, a global medical technology company, announced the launch of its 11th manufacturing facility in Mexico, which is located at Hermosillo, Sonora. The plant will manufacture and supply medical devices such as plastic packing syringes in Latin America region.

Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings – Impact of Coronavirus (Covid-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260 million cases and 5.2 million deaths due to coronavirus disease (COVID-19) were reported till November 29, 2021, across the globe.

The product development has noticed profound disruption, as workers have to adjust to remote work environments to decrease lab capacity because of COVID pandemic. Clinical trials are also being severely affected with disruptions in both new enrolment and in keeping record of patient therapies. According to the clinicaltrials.gov, as of April 2020, there were more than 2,850 trials and approximately 900,000 patients enrolled at trial sites in regions that were in partial or complete lockdown due to COVID-19 restrictions. The R&D labs are operating at below 50% of normal capacity. According to the World Health Organization (WHO), in 2020 there were only 32 antibacterial treatments in clinical development, targeting the WHO’s list of priority pathogens and of these, only 6 fulfil at least one of the criteria as defined by WHO. WHO developed a list of priority pathogens for which antibiotics are urgently needed and regularly performs an analysis of the clinical and pre-clinical antibacterial pipelines during the COVID-19 pandemic. It also recently gathered experts to identify Target Product Profiles (TPPs) for the most essential and missing antibacterials.

WHO furthermore works with a variety of international partners to set up new mechanisms for driving investment and innovation in R&D.

Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings: Restraint

Growth of the Brazil injectable drugs market for hospitals and ambulatory settings is likely to be hampered in the near future, owing to various drawbacks of the Brazil healthcare system. Factors such as lack of doctors and nurses is one of the main reasons for the poor public health in the urban area. Brazil has proportionately fewer doctors compared to other developed countries.

Studies show that only 8% of Brazilian doctors are working in cities. Weak or ambiguous patent laws are also expected to limit growth of the market. Countries in Latin America have adopted different approaches for intellectual property protection. Ambiguity regarding pricing of drugs is also prevalent in the region. For example, prices of public sector pharmaceutical drugs in Latin America vary than those sold through the private sector.

Key Players

Major players operating in the Brazil injectable drugs market for hospitals & ambulatory settings include Becton, Dickinson and Company, Pfizer, Inc., Novo Nordisk A/S, Gerresheimer AG, B. Braun Medical Inc., Grifols S.A, Baxter International, Inc., Fresenius Kabi AG, Mylan N.V., Bayer AG, F. Hoffmann-La Roche AG, Farmoquimica S.A., Novartis International AG, Eli Lily and Company, União Química Farmacêutica, Nacional S.A., Cristália, Aspen Pharmacare Holdings Limited, Blau Farmaceutica S.A., Halex Istar Indústria, Farmacêutica SA, Eurofarma, Ache Laboratorios Farmaceuticos SA, Laboratorio Teuto Brasileiro S/A, EMS Pharma, and Hipolabor Farmaceutica Ltda.

Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site. Injectable delivery facilitates rapid absorption of drug from various route of administration such as subcutaneous, intravenous, and intramuscular. Injectable delivery increases the bioavailability of the drug at the systemic circulation. The increasing prevalence of chronic diseases, technological advancements, demand for individual therapy, awareness about drug metabolism among the population, and requirement of controlled drug release are the major factors driving the growth of the Brazil injectable drugs market for hospitals & ambulatory settings.

Brazil injectable drugs market for hospitals & ambulatory settings is estimated to be valued at US$ 7,960.0 Mn in 2021 and is expected to increase to US$ 17,858.5 Mn by 2028, witnessing a CAGR of 8.4% during the forecast period.

Market Dynamics

Increasing government initiatives in the healthcare sector of Brazil, rising drug launches and approvals, increasing prevalence of chronic diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Brazil injectable drugs market for hospitals & ambulatory settings.

The healthcare sector of Brazil is witnessing significant reforms in recent times owing to increasing initiatives by the government, agreements between multinational pharmaceutical companies and rising healthcare expenditure which is driving growth of the Brazil injectable drugs market for hospitals and ambulatory settings.

For instance, in June 2020, the government of Brazil announced an agreement with Oxford University and pharmaceutical company, AstraZeneca, to produce a promising coronavirus vaccine that is undergoing tests. The Brazilian Health Ministry said in a press conference that the country will pay US$ 127 million and receive material to produce 30.4 million doses in two batches in December and January.

Furthermore, in June 2019, government of the state of São Paulo, Brazil announced that they are seeking volunteers to test a new injectable drug preventing HIV infection using long-term injections as an alternative to the daily oral medication.

Moreover, increasing vaccination drives for certain diseases are also expected to aid growth of the Brazil Injectable drugs market for hospitals and ambulatory settings. For instance, in March 2020, Brazil initiated its National Flu Vaccination Campaign in three phases against influenza. The vaccine is indicated for anyone over 6 months of age, except those who have had allergic reactions to previous doses.

Key features of the study:

  • This report provides an in-depth analysis of the Brazil injectable drugs market for hospitals & ambulatory settings market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Brazil injectable drugs market for hospitals & ambulatory settings, based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Becton, Dickinson and Company, Pfizer, Inc., Novo Nordisk A/S, Gerresheimer AG, B. Braun Medical Inc., Grifols S.A, Baxter International, Inc., Fresenius Kabi AG, Mylan N.V., Bayer AG, F. Hoffmann-La Roche AG, Farmoquimica S.A., Novartis International AG, Eli Lily and Company, União Química Farmacêutica, Nacional S.A., Cristália, Aspen Pharmacare Holdings Limited, Blau Farmaceutica S.A., Halex Istar Indústria, Farmacêutica SA, Eurofarma, Ache Laboratorios Farmaceuticos SA, Laboratorio Teuto Brasileiro S/A, EMS Pharma, and Hipolabor Farmaceutica Ltda.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Brazil injectable drugs market for hospitals & ambulatory settings report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Brazil injectable drugs market for hospitals & ambulatory settings

Detailed Segmentation:

  • Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Product Type:
    • Pre-filled syringes
    • Auto-injectors
    • Pre-filled Pens
    • Pre-mixed IV Bags
    • Others
  • Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Drug Class:
    • Anesthesia
    • Antibiotics
    • Antidotes
    • Antiemetic
    • Anti-infective
    • Anti-Thrombolytic
    • Muscle Relaxant
    • Non Opioids
    • Opioids
    • Sedatives
    • Others
  • Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Mode of Delivery:
    • Intramuscular (IM)
    • Intravenous (IV)
    • Subcutaneous (SC)
    • Others (Epidural and Intrathecal)
  • Company Profiles
    • Becton, Dickinson and Company*
      • Company highlights
      • Product Portfolio
      • Key Highlights
      • Financial performance
      • Strategies
    • Pfizer Inc.
    • Novo Nordisk A/S
    • Gerresheimer AG
    • Braun Medical Inc.
    • Grifols S.A.
    • Baxter International, Inc.
    • Fresenius Kabi AG
    • Mylan N.V.
    • Bayer AG
    • Hoffmann-La Roche AG
    • Farmoquimica S.A.
    • Novartis International AG
    • Eli Lily and Company
    • União Química Farmacêutica
    • Nacional S.A.
    • Cristália
    • Aspen Pharmacare Holdings Limited
    • Blau Farmaceutica S.A.
    • Halex Istar Indústria
    • Farmacêutica SA
    • Eurofarma
    • Ache Laboratorios Farmaceuticos SA
    • Laboratorio Teuto Brasileiro S/A
    • Hipolabor Farmaceutica Ltda.
    • EMS Pharma

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The Brazil injectable drugs market for hospitals & ambulatory settings is estimated to be valued at US$ 7,960.0 million in 2021 and is expected to exhibit a CAGR of 8.4% over the forecast period (2021-2028).
The increasing government initiatives in the healthcare sector of Brazil, increasing drug launches and approvals, and increasing prevalence of chronic diseases are the major factors that are expected to drive the market growth over the forecast period. 
Pre-filled syringes segment is expected to hold a major market share. Pre-filled syringes segment is estimated to account for 37.8% market share in 2021 and 39.2% by 2028.
Major factors hampering the growth of the market include various drawbacks in healthcare system of Brazil.
Major players operating in the market include Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, B. Braun Medical Inc., Grifols S.A, Baxter International, Inc., Fresenius Kabi AG, Mylan N.V., Bayer AG, F. Hoffmann-La Roche AG, Farmoquimica S.A., Novartis International AG, Eli Lily and Company, União Química Farmacêutica, Nacional S.A., Cristália, Aspen Pharmacare Holdings Limited, Blau Farmaceutica S.A., Halex Istar Indústria, Farmacêutica SA, Eurofarma, Ache Laboratorios Farmaceuticos SA, Laboratorio Teuto Brasileiro S/A, EMS Pharma, and Hipolabor Farmaceutica Ltda.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo